Details for Patent: 10,238,620

Which drugs does patent 10,238,620 protect, and when does it expire?

Patent 10,238,620 protects SILENOR and is included in one NDA.

This patent has eleven patent family members in four countries.

Summary for Patent: 10,238,620

Title:	Methods of using low-dose doxepin for the improvement of sleep
Abstract:	Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).
Inventor(s):	Rogowski; Roberta L. (Rancho Santa Fe, CA), Dube; Susan E. (Carlsbad, CA), Jochelson; Philip (San Diego, CA), Kavey; Neil B. (Chappaqua, NY)
Assignee:	Pernix Sleep, Inc. (Morristown, NJ) ProCom One, Inc. (San Marcos, TX)
Application Number:	15/864,440
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,238,620
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

Drugs Protected by US Patent 10,238,620

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-001	Mar 17, 2010	AB	RX	Yes	No						TREATMENT OF INSOMNIA
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-002	Mar 17, 2010	AB	RX	Yes	Yes						TREATMENT OF INSOMNIA

International Family Members for US Patent 10,238,620

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2687118
Canada	2687124
European Patent Office	2026792
Japan	2009537553
Japan	2009537554